Trinds, a new contract research organization born from the Cooperative International Neuromuscular Research Group (CINRG) academic consortium, received an investment from CureDuchenne Ventures.
The amount of the deal was not disclosed.
The company will use the funds to accelerate its operations.
Led by Lauren Morgenroth, Chief Operating Officer, and Heather Gordish-Dressman, President of the Board, Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS) provides specialized clinical trial support and post marketing solutions for neuromuscular, particularly Duchenne, clinical research.
The company provides four main solutions to the pharmaceutical and biotechnology industries as well as academic investigators and clinical centers for their clinical needs: clinical operations, data management, biostatistics and study measurements.
CureDuchenne Ventures, LLC, is the investment arm of CureDuchenne, a non-profit dedicated to curing Duchenne muscular dystrophy.